Mechanism of action of and resistance to quinolones

Anna Fàbrega,1 Sergi Madurga,2,3 Ernest Giralt2,4 and Jordi Vila1*
1Department of Microbiology, Hospital Clinic, School of Medicine, University of Barcelona, Spain.
2Institute for Research in Biomedicine, Barcelona, Spain.
Departments of 3Physical Chemistry & IQTCUB and 4Organic Chemistry, University of Barcelona, Spain.

Summary

Fluoroquinolones are an important class of wide-spectrum antibacterial agents. The first quinolone described was nalidixic acid, which showed a narrow spectrum of activity. The evolution of quinolones to more potent molecules was based on changes at positions 1, 6, 7 and 8 of the chemical structure of nalidixic acid. Quinolones inhibit DNA gyrase and topoisomerase IV activities, two enzymes essential for bacteria viability. The acquisition of quinolone resistance is frequently related to (i) chromosomal mutations such as those in the genes encoding the A and B subunits of the protein targets (gyrA, gyrB, parC and parE), or mutations causing reduced drug accumulation, either by a decreased uptake or by an increased efflux, and (ii) quinolone resistance genes associated with plasmids have been also described, i.e. the qnr gene that encodes a pentapeptide, which blocks the action of quinolones on the DNA gyrase and topoisomerase IV; the aac(6′)-Ib-cr gene that encodes an acetylase that modifies the amino group of the piperazin ring of the fluoroquinolones and efflux pump encoded by the qepA gene that decreases intracellular drug levels. These plasmid-mediated mechanisms of resistance confer low levels of resistance but provide a favourable background in which selection of additional chromosomally encoded quinolone resistance mechanisms can occur.

Fluoroquinolones are an important class of broad-spectrum antibacterial agents, whose spectra of activity has been parallel to modifications in the structure of the first quinolone, nalidixic acid. Nalidixic acid, which can be considered as the first generation of quinolones, was introduced for clinical use in 1962 (Lesher et al., 1962) and was initially administered to treat Gram-negative urinary tract infections in humans and animals (Suh and Lorber, 1995). Subsequently, the molecular structures of quinolones were modified to improve their antimicrobial properties and pharmacokinetic profiles (Ball, 1998; 2000; Kim et al., 2001). On the basis mainly of their antibacterial spectra, quinolone drugs are classified into generations. The second generation of quinolones started with fluoroquinolones obtained by fluoridation of the quinolone molecule at position C6. The first fluoroquinolone, norfloxacin, was synthesized in 1978 and became available for clinical use in 1986 (Paton and Reeves, 1988). Ciprofloxacin, one of the most used fluoroquinolones, was introduced into the clinical market in 1987. Fluoroquinolone drugs are active against a wide range of Gram-negative and Gram-positive pathogens and show improved oral absorption and systemic distribution. Thus, the clinical applications of these compounds have been extended to the treatment of lower respiratory tract infections, skin and soft tissue infections, sexually transmitted diseases and urinary tract infections (Chu, 1996). However, this second generation of quinolones has limited activity against a number of clinically relevant Gram-positive bacteria and anaerobes (Ball, 1998; Ball et al., 1998; Zhanel et al., 2002). Since 1987, structural variations of fluoroquinolones have provided numerous new agents suitable for the treatment of a variety of bacterial infections. In the third generation of quinolones, more potent fluoroquinolones were developed, such as levofloxacin, gatifloxacin (Perry et al., 1999) and moxifloxacin (Barrett, 2000), which exhibit improved bactericidal activity against Gram-positive bacteria. The fourth generation of quinolone drugs, such as gemifloxacin (Lowe and Lamb, 2000), shows good activity against Gram-positive cocci and significant activity against anaerobes (Bhavnani and Ballow, 2000; Kim et al., 2001).

Structure of the quinolones

From the structural perspective, quinolones are heterocycles with a bicyclic core structure (Fig. 1). The carboxylic acid group at position 3 and the carbonyl at position 4

Received 30 April, 2008; revised 20 August, 2008; accepted 24 August, 2008. *For correspondence. E-mail jvila@ub.edu; Tel. (+34) 93 2275522; Fax (+34) 93 2279372.
seem to be essential for the activity of the quinolones. In addition, bulky substituents on one face of the bicyclic core, namely at positions 1 and 7 and/or 8, are permissible and they seem to play a relevant role to determine the quinolone antibiotic spectrum. With respect to these substituents, most quinolones can be arranged into three main categories: piperazinyl-, pyrrolidinyl- and piperidinyl-type side-chains (Hu et al., 2003). Piperazinyl-based quinolones usually have a wide Gram-negative coverage but a limited Gram-positive spectrum (e.g. ciprofloxacin and levofloxacin). On the other hand, piperidinyl- and pyrrolidinyl-based quinolones have a more balanced spectrum (e.g. gemifloxacin).

Mechanism of action

Quinolone antibiotics inhibit DNA synthesis by targeting two essential type II topoisomerases, DNA gyrase and topoisomerase IV (Topo IV). Both targets allow one double-stranded DNA molecule to pass through another, followed by religation of the original strand, thereby changing the linking number of DNA by two in each enzymatic step. Although both enzymes show a high degree of similarity in their structures and functions, their specific function during DNA replication differs (Levine et al., 1998).

DNA gyrase is an enzyme found only in bacteria. This enzyme uses the energy of ATP hydrolysis to introduce negative supercoils into DNA (Gellert et al., 1976; Champoux, 2001; Corbett and Berger, 2004). This unidirectional supercoiling activity is caused by chiral wrapping of the DNA (Liu and Wang, 1978a,b) around a specialized domain of the enzyme before strand passage (Reece and Maxwell, 1991; Kampranis and Maxwell, 1996; Corbett et al., 2004; Ruthenburg et al., 2005). Negative DNA supercoiling is essential for chromosome condensation, relieving torsional strain during replication, and promoting local melting for vital processes such as transcript initiation by RNA polymerase (Levine et al., 1998; Wang, 2002). DNA gyrase is an excellent target for quinolones because it is not present in eukaryotic cells and is essential for bacterial growth. This enzyme comprises two subunits, A (97 kDa) and B (90 kDa), which form an A₂B₂ tetramer (Higgins et al., 1978; Liu and Wang, 1978; Klevan and Wang, 1980). The A subunit is encoded by the gyrA gene and is involved mainly in DNA breakage and reunion, while the B subunit is encoded by the gyrB gene and exhibits ATPase activity (Ali et al., 1993; 1995). To develop supercoiling activity, the DNA gyrase generates a pair of single-stranded breaks of a first (G or gate) DNA segment in which the broken ends are 4 bp apart (Morrison and Cozzarelli, 1979; Wang, 1998). These two DNA ends are separated, thereby forming a transient gate, through which the second (T or transported strand) DNA segment, wrapped around the DNA gyrase, is then
passed. In this process, the C-terminus of the GyrA subunit is responsible for the unique negative supercoiling activity of the DNA gyrase. This conclusion has been made on the basis of observations that mutants lacking the C-terminus lose their capacity to form negative supercoils (Kampranis and Maxwell, 1996; Kampranis et al., 1999).

In addition to quinolones, naturally occurring bacterial DNA gyrase inhibitors, such as coumarins, which include novobiocin, are also antibacterial agents (Maxwell, 1993; Kim and Ohemeng, 1998). Coumarins inhibit the ATPase activity of the DNA gyrase by competing with ATP for binding to the GyrB subunit. However, because of side-effects, to date few pharmacetically useful drugs have been derived from coumarins. Topoisomerase IV has two functions in the cell. First, it serves as a decatenating enzyme that resolves interlinked daughter chromosomes after DNA replication. Topoisomerase IV is required at the terminal stages of DNA replication for unlinking newly replicated daughter chromosomes (Orlica and Zhao, 1997). These links must be removed in order to segregate chromosomes (and plasmids) into daughter cells so that cell division can be completed. The second function, shared with the DNA gyrase, of Topo IV is to relax positive supercoils. Like the DNA gyrase, Topo IV uses a double-strand passage mode; however, the mechanism of this passage differs. The gyrase wraps the DNA around itself, while Topo IV does not. Topoisomerase IV is also a heterotetramer made of two A subunits (ParC) and two B subunits (ParE) (Kato et al., 1990). ParC is encoded in the parC gene (also called grlA gene in Staphylococcus aureus) and ParE is encoded in the parE gene. These subunits share about 35% identity with GryA and GyrB of the DNA gyrase. During the catalytic cycle, Topo IV binds the gate (G) segment of the DNA. Upon binding of a second DNA segment, the transport (T) segment, the ParE subunits dimerize around the T segment DNA. The enzyme then cleaves the G segment, passes the T segment through the break and reseals the broken duplex. ParC are the subunits responsible for DNA binding and the cleavage and religation reaction, while ParE are responsible for ATP binding and hydrolysis (Levine et al., 1998).

However, some microorganisms such as Mycobacterium spp., Campylobacter spp., Corynebacterium spp. and Helicobacter pylori do not possess Topo IV and it has been shown that the DNA gyrase of Mycobacterium smegmatis presents an enhanced decatenating activity and, hence, likely assumes the role of Topo IV in these microorganisms (Manjunatha et al., 2002). The main physiological role, of both DNA gyrase and Topo IV, is the replication and transcription of the DNA and Topo IV in addition to the decatenation of daughter replicons following DNA replication. The DNA gyrase may also play a role in the organization of the chromosome as it has been suggested that it is organized in negative supercoiled domains.

As mentioned above, quinolone drugs are active against type II topoisomerases and act by blocking DNA replication and inhibiting synthesis and cell division (Vila, 2005). The mechanism of quinolone inhibition occurs via formation of a ternary cleavage complex with the topoisomerase enzyme and DNA Figure 2 (Hiasa and Shea, 2000). However, the molecular details of the mode of action of these drugs remain unclear.

It is accepted that for quinolones to inhibit DNA gyrase activity, they must form a stable interaction with the DNA gyrase–DNA complex. To overcome the lack of crystallographic data for the ternary complex, computational tools,
such as molecular docking, are useful for predicting the structures of protein–ligand complexes and providing information on the modes of interaction between ligands and receptors. Several docking studies have been performed with the ATP binding site of the GyrB subunit (Boehm et al., 2000; Schulz-Gasch and Stahl, 2003) or outside the QRDR region of GyrA (Ostrov et al., 2007). A docking study of fluoroquinolones to the QRDR region of the DNA gyrase recently put forward a structural hypothesis of their binding mode (Madurga et al., 2008). It was found that Asp-87 is critical in the binding of quinolone drugs because it interacts with the positively charged nitrogen of the fluoroquinolones. In addition, Arg-121, located next to the active-site tyrosine, was postulated to be another relevant point of binding (Madurga et al., 2008).

Mechanisms of resistance

The acquisition of quinolone resistance may be related to: (i) chromosomal mutations in genes encoding the protein targets, or mutations causing reduced drug accumulation, either by a decreased uptake or by an increased efflux, and (ii) plasmid-located genes associated with quinolone resistance (Vila, 2005).

Chromosome-mediated quinolone resistance

Enterobacteriaceae. The process by which susceptible strains become highly fluoroquinolone-resistant is thought to be a result of a series of sequential steps. Overall, in Enterobacteriaceae the first step is often a single mutation in the gyrA gene, which confers low-level quinolone resistance [minimal inhibitory concentration (MIC) of ciprofloxacin of 0.125–0.25 mg l⁻¹]. The acquisition of a second mutation either in the amino acid codon Ser-80 or in the amino acid codon Glu-84 of the parC gene is associated with a moderate level of ciprofloxacin resistance (1–4 mg l⁻¹). A third mutation, the second in gyrA, is associated with a high level of ciprofloxacin resistance (8–64 mg l⁻¹), and a fourth mutation, the second in parC, is associated with the highest level of resistance (128 mg l⁻¹) (Table 1) (Vila et al., 1996). Therefore, several mutations are needed to produce a high level of quinolone resistance. The most important mutations leading to a quinolone-resistant phenotype in Escherichia coli are in the gyrA gene, mainly amino acids Ser-83–Leu and Asp-87–Asn (this position can occasionally be changed to Val, Tyr and Gly), and in the parC gene changing Ser-80–Arg (Ile can also be found) and Glu-84–Val (Gly can also be found) (Nakamura et al., 1989; Vila et al., 1994; Hiasa, 2002). Nakamura and colleagues (1989) found that mutations in the gyrB gene also contribute to low-level quinolone resistance. Yoshida and colleagues (1991) evaluated mutations in gyrB and found two mutations: Asp-426–Asn (associated with a higher level of quinolone and fluoroquinolone resistance) and Lys-447–Glu (associated with hypersusceptibility to fluoroquinolones but nalidixic acid resistance). However, in E. coli clinical isolates this does not appear to be a common phenomenon, since an Asp-426–Asn change was only found in one out of 27 E. coli clinical isolates investigated (Vila et al., 1994). No mutations were found in the parE gene in 27 E. coli clinical isolates (Ruiz et al., 1997). However, Sorlozano and colleagues (2007) have recently described the acquisition of a new previously undetected mutation within the QRDR of the parE gene at position 458 (Ser→Ala). The above mentioned mutations can be extrapolated to other Enterobacteriaceae. In addition to point mutations in the gyrA gene, the decreased susceptibility to fluoroquinolones may be due to the decreased accumulation of the quinolone or to the presence of some plasmid mediated quinolone resistance mechanism (see specific section). Moreover, the overexpression of efflux

| Table 1. The most frequent amino acid substitutions found in GyrA and ParC of different Enterobacteriaceae. |
| --- |
| **Amino acid change** | **MIC (mg l⁻¹)** |
| **Microorganism** | **GyrA** | **ParC** | **CIP** |
| *Escherichia coli* wt | Ser-83 | Asp-87 | Ser-80 | Glu-84 | 0.25–4 |
| | Leu | Arg | Lys | 1–4 |
| | Leu | Asn/Tyr | 4 |
| *Salmonella* spp. wt | Ser-83 | Asp-87 | Ser-80 | 0.25–2 |
| | Phe | Gly/Tyr | 0.12–0.5 |
| | | Ile | 4 |

MIC, minimum inhibitory concentration; CIP, ciprofloxacin.
pumps may also play a role in the high level of resistance in strains with two or three mutations.

The decrease of drug accumulation can be associated with: (i) an upregulation of certain cell envelope proteins, which can facilitate extrusion of these agents – these proteins are energy-dependent efflux systems that can be specific to a drug or can have broad specificity, then called multidrug transporters, and (ii) decrease of permeability often related to decreased expression of porins, which are outer membrane proteins that form channels for passive diffusion and are only present in Gram-negative bacteria (Markham and Neyfakh, 2001; Jacoby, 2005).

Active efflux transporters have been classified into five superfamilies: (i) the major facilitator superfamily (MFS), (ii) the ATP-binding cassette (ABC) family, (iii) the resistance/nodulation/division (RND) family, (iv) the small multidrug resistance (SMR) family and (v) the multidrug and toxic compound extrusion (MATE) family. These antibiotic efflux pumps utilize the energy of the proton-motive force to expel antibiotics, with the exception of the ABC family that utilizes the energy generated from the hydrolysis of ATP. A remarkable feature of some of these transporters is wide range of substrates that are recognized by a single pump protein (Poole, 2000a; Fàbrega et al., 2008).

The Enterobacteriaceae, as most Gram-negative bacteria, are protected by the action of multidrug efflux transporters, which usually belong to the RND family followed by members of the MFS family and are expressed in a constitutive way leading to their intrinsic resistance phenotype and providing immediate response to structurally diverse antimicrobial agents by means of their overexpression (Nikaido, 1996; Zgurskaya and Nikaido, 2000).

There are many genes that are assumed to encode a drug transporter protein in Enterobacteriaceae because of sequence similarities in their open reading frames (ORFs). However, only AcrAB/TolC overexpression has been shown to play a major role as a main efflux pump implicated in extruding quinolones (Oethinger et al., 2000; Webber and Piddock, 2001; Schneiders et al., 2003; Baucheron et al., 2004; Hasdemir et al., 2004; Chen et al. 2007). This efflux pump, which belongs to the RND superfamily, is a three-component system: acrA and acrB genes are co-transcribed from the same operon and the resulting proteins are AcrA, the membrane fusion protein (MFP), and AcrB, the energy-dependent transport protein anchored in the inner membrane respectively. The third component is TolC, the outer membrane protein (Okusu et al., 1996; Fàbrega et al., 2008). The inactivation of the acrB or tolC genes in fluoroquinolone-susceptible strains shows its contribution to the intrinsic resistance levels to fluoroquinolones and other antibiotics (tetracyclines, chloramphenicol, β-lactams, trimethoprim, rifampin, ami-

In addition to AcrAB overexpression there are particular situations described in E. coli and Salmonella enterica serotype Typhimurium (S. Typhimurium) when fluoroquinolone-resistant mutants have been obtained ‘in vitro’ after acrAB inactivation. These mutants have reached this phenotype by overexpressing another efflux pump, AcrEF (also an RND family member), which may be a compensatory mechanism and whose substrate specificity is very similar to that of AcrAB (Jellen-Ritter and Kern, 2001; Olliver et al., 2005).

The mechanisms of resistance by which AcrAB can be overexpressed are those that affect the regulatory genes that determine the protein levels. acrAB genes are regulated by four known transcriptional factors. Rob, MarA and SoxS are transcriptional activators that belong to the XylS/AraC family (Gallegos et al., 1997) and promote acrAB expression by binding to the marbox found upstream of the acrAB operon; whereas AcrR is the local repressor for this pump, localized upstream of acrA gene but transcribed into the opposite direction (Fig. 3) (Gallegos et al., 1997; Martin et al., 1999; Martin and Rosner, 2002).

The SoxS protein belongs to the SoxRS regulon. In this system, the soxS gene is only transcribed in the presence of an oxidized form of the SoxR protein (Fig. 3) (Amabile and Demple, 1991; Pomposiello and Demple, 2000). Among E. coli clinical isolates that show a MAR phenotype, it is frequent to find overexpression of SoxS (Oethinger et al., 1998; Kern et al., 2000; Webber and Piddock, 2001). Constitutive soxS expression can be triggered, in principle, by mutations within the soxR gene that render the protein constitutively active, by mutations in the soxS promotor that turn on its own transcription constitutively or by mutations in other genes that regulate the redox status of SoxR (Amabile and Demple, 1991). To date, only mutations randomly distributed within the soxR gene have been found as a factor responsible for increased soxS expression in E. coli and S. Typhimurium clinical isolates, as these mutations lead SoxR to be in a permanent activated state (Nunoshiba and Demple, 1994; Koutsolioutsou et al., 2001; 2005; Webber and Piddock, 2001).

The MarA protein belongs to the marORAB operon, where MarR is a transcriptional repressor (Fig. 3). Once MarA is transcribed it can autoactivate the operon itself by binding to the marbox upstream from the marRAB promoter (Sulavik et al., 1997; Martin et al., 1999; Martin and Rosner, 2002). To date, mutations that trigger overexpression of MarA have only been found in E. coli, usually within the codifying sequence of MarR, and focus their
effects on AcrAB, because when this pump is inactivated, overproduction of MarA becomes useless at increasing fluoroquinolone resistance (Okusu et al., 1996; Oethinger et al., 1998).

The Rob protein also belongs to the same family of activators but differs in size, as only its N-terminal domain, which is the DNA-binding domain, shows homology with both MarA and SoxS proteins. It has been shown that Rob activates many regulatory genes leading to a global effect, although the magnitude of its effects is modest (Fig. 3). No clinical data have been reported to date linking fluoroquinolone resistance with Rob overexpression.

The last of the four regulators for AcrAB is AcrR, the repressor that controls acrAB expression; it only affects the level of these two structural proteins (Fig. 3) (Okusu et al., 1996; Webber and Piddock, 2001). Escherichia coli, S. enterica and Klebsiella pneumoniae clinical isolates as well as MAR mutants selected 'in vitro' can overexpress AcrAB by acquiring mutations within the transcriptional DNA that inactivate the acrR gene (Jellen-Ritter and Kern, 2001; Webber and Piddock, 2001; Schneiders et al., 2003; Olliver et al., 2004).

In addition to these regulatory loci generally found in Enterobacteriaceae, it has been reported that some bacterial species have a homologue of MarA, dubbed RamA, which belongs to the same family of transcriptional activators. This gene was first described in K. pneumoniae (George et al., 1995), but it is also present in Salmonella spp., Enterobacter aerogenes and Enterobacter cloacae. However, it is absent in E. coli. The resulting protein, which has also been shown to bind to the marbox, when overexpressed in a susceptible E. coli strain, allowed this microorganism to display a MAR phenotype related to both increased efflux and loss of the OmpF porin (see below for porin regulation). This can be explained by assuming that RamA may trigger the same effect as MarA or SoxS (George et al., 1995; Schneiders et al., 2003; van der Straaten et al., 2004). Overexpression of the ramA gene has been detected in some

| Genes: | Transcriptional activator | Transcriptional regulator |
|-------|--------------------------|--------------------------|
| Genes product: | protein | mRNA |
| Genetic element: | marbox |

Fig. 3. Regulation of acrAB, tolC and ompF genes involved in decreasing the internal accumulation of quinolones. MarA, SoxS and Rob are the transcriptional activators which turn on these genes. AcrR is the local repressor and only affects AcrAB expression.

© 2008 The Authors
Journal compilation © 2008 Society for Applied Microbiology and Blackwell Publishing Ltd, Microbial Biotechnology, 2, 40–61
fluoroquinolone-resistant clinical *K. pneumoniae* strains in concordance with elevated levels of AcrAB when neither MarA nor SoxS are overexpressed. In addition, RamA overexpression in MAR strains overexpressing AcrAB has been justified by the presence of mutations within the encoding region of the repressor leading to its inactivation. In addition, a deletion in the putative RamR binding site upstream ramA prevents RamR binding and thus, its repressor effect over RamA. The regulatory effects of RamA in fluoroquinolone resistance acquisition may play a key role in strains lacking an altered level of any of the other regulators, such as MarA, SoxS or AcrR, suggesting that the role of these regulators is not as significant as in *E. coli* (Abouzeed et al., 2008). However, other studies compromise these conclusions as they reveal that ramA inactivation in some *S. Typhimurium* clinical isolates showing a MAR phenotype does not result in any change in ciprofloxacin susceptibility (van der Straaten et al., 2004).

These mutations in the regulatory loci are acquired individually as only one of these genes is completely affected (Oethinger et al., 1998; Kern et al., 2000; Webber and Piddock, 2001). However, an exception has been reported in *K. pneumoniae* when both genetic mechanisms, increased RamA expression and acrR inactivation, have sometimes been found at the same time (Schneider et al., 2003). A reasonable explanation may be that some of these transcriptional factors (MarA, SoxS or Rob) show overlapping effects as many of the genes of their regulons are the same (Martin et al., 1999; Martin and Rosner, 2002).

Despite the proposal of all these mechanisms further investigation is needed for a complete explanation, for example, when: (i) fluoroquinolone resistance has at times been reported not to be linked to marOR, soxRS or acrR mutations, even when AcrAB is overproduced in *E. coli* and *Salmonella* strains, suggesting that mutations in unidentified chromosomal loci may turn on other regulatory mechanisms that increase efflux by AcrAB (Oethinger et al., 2000; Piddock et al., 2000; Webber and Piddock, 2001; Chu et al., 2005; Koutsolioutou et al., 2005), (ii) an increasing level of SoxS linked with fluoroquinolone resistance has been reported with an absence of an AcrAB-inducing effect, suggesting that alternative ways may be implicated (Oethinger et al., 1998; Oethinger et al., 2000; Webber and Piddock, 2001; Koutsolioutou et al., 2005), and (iii) inactivation of the acrB gene is performed and there is an important decrease in resistance in quinolone-resistant mutants, but in contrast, the wild-type conditions are not reached, suggesting that another mechanism may contribute (Baucheron et al., 2004).

Furthermore, the outer membrane protein profile has also been studied in strains with a high level of fluoroquinolone resistance. It has been found that the major outer membrane proteins of *E. coli*, OmpF and OmpC (as their analogous proteins in other bacterial species, like OmpK35 and OmpK36, respectively, found in *K. pneumoniae* (Hernández-Allés et al., 2000)), when downregulated play a role in decreasing the outer membrane permeability and thereby reducing the internal accumulation of the antibiotic leading to a two- to fourfold increase in the MIC of fluoroquinolones (Mizuno et al., 1984; Hirai et al., 1986; Martínez-Martínez et al., 2002). These two genes, *ompF* and *ompC*, are transcriptionally regulated, depending on the temperature and the osmolarity of the media, by the two-component regulatory system OmpR-EnvZ that mediates both positive and negative control. There is also a post-transcriptional control by the small regulatory RNA molecules micC and micF which downregulate OmpC and OmpF expression respectively. MicC is complementary to the leader sequence of the *ompC* mRNA (Chen et al., 2004), whereas micF is partially complementary to the 5′ end of the *ompF* mRNA (Mizuno et al., 1984). The micF promoter contains a marbox so that it is turned on by MarA (Cohen et al., 1988), SoxS (Chou et al., 1993), Rob (Ariza et al., 1995) and RamA (George et al., 1995) what can downregulate OmpF expression independently of OmpC production (Fig. 3). This explains why it is more frequent to find only an OmpF loss or decrease in fluoroquinolone-resistant strains, whereas few cases have reported only an OmpC reduction, or both proteins at the same time (Hirai et al., 1986; Cohen et al., 1989; Tavío et al., 1999; Hernández-Allés et al., 2000; Hasdemir et al., 2004; Chenia et al., 2006). This deficiency in porins has been reported to achieve a significant effect only when mutations occur within the QRDR or efflux mechanisms appear simultaneously. Furthermore, an altered protein profile seems to be linked with AcrA overexpression (Deguchi et al., 1997; Hernández-Allés et al., 2000; Martínez-Martínez et al., 2002; Hasdemir et al., 2004).

Despite this general information, other efflux systems as well as particular situations affect bacteria individually:

(i) *Escherichia coli*. Concerning quinolone resistance, only four efflux pumps have been able to show a clear implication in quinolone efflux by overexpression from a plasmid: (i) AcrAB and (ii) AcrEF which confer an eight- and a fourfold increase in norfloxacin and nalidixic acid resistance respectively, (iii) MdfA, which belongs to the MFS superfamily and (iv) YdhE (also called NorE), belonging to the MATE superfamily. These two latter proteins, MdfA and YdhE, confer an eightfold increase in norfloxacin resistance and do not affect nalidixic acid susceptibility (Table 5) (Edgar and Bibi, 1997; Nishino and Yamaguchi, 2001; Yang et al., 2003). However, another study has shown that the inactivation in *E. coli* strain W3110 of either the
mdfA or acrEF genes does not trigger any change in fluoroquinolone susceptibility (Sulavik et al., 2001).

When AcrAB overexpression is in combination with other multidrug resistance pumps, such as MdfA or YdhE, it has been shown to confer a synergistic effect (7- and 11-fold increased in ciprofloxacin and norfloxacin resistance respectively) (Yang et al., 2003). Despite this effect, it has been suggested that resistance levels mediated by individual or simultaneous overexpression of pumps may have an upper limit, approximately a 10-fold increase in drug resistance, because when a determined high level of expression for these proteins is reached, the correlation with high efflux of the antibiotic and its MIC is no longer provided (Webber and Piddock, 2001; Yang et al., 2003).

(ii) Salmonella enterica. Fluoroquinolone-resistant strains have been able to show a substantial increased expression of AcrF, EmrD or MdfA (a part from AcrB), whereas overexpression of TolC, MdtB, MdtC or EmrA is also achieved but to a lesser extent (Chen et al., 2007). However, the individual inactivation of AcrEF, MdtABC, EmrAB, MdfAB or even AcrD (but maintaining an active AcrAB) does not lead to any significant change in the MIC of any fluoroquinolone, suggesting that limited or no role is played (Olliver et al., 2005; Chen et al., 2007).

(iii) Klebsiella pneumoniae. Other ORFs have been found to extrude quinolones. An example of these pumps are two MFS members: KmrA which has been reported to be overexpressed in a K. pneumoniae clinical isolate showing the MAR phenotype (Ogawa et al., 2006) and KdeA, a homologue of MdtA of E. coli, whose expression level is similar in the same clinical isolate and in the ATCC strain, suggesting a possible role in the intrinsic resistance in Klebsiella (Table 5) (Ping et al., 2007).

Non-fermenting Gram-negative bacteria. In microorganisms such as Pseudomonas aeruginosa and Acinetobacter baumannii, a single mutation in the gyrA gene is sufficient to cause clinically important levels of resistance to fluoroquinolones as these bacteria already show an intrinsic resistance to these antibacterial agents, likely due to low permeability or constitutive expression of some efflux pump(s) or the interplay between both. Therefore, this decreased susceptibility (low level of resistance) can favour the acquisition of a mutation and increase the MIC of fluoroquinolones.

- Pseudomonas aeruginosa. Beside mutations in target genes, DNA modifications increasing the efflux of the antibiotics by overexpression of the efflux pump systems play an important role in triggering resistance. The most important group of efflux pumps found in P. aeruginosa is the RND family (Vila and Martínez, 2008). Nine different RND efflux pumps have been characterized (Table 5): (i) mexAB-oprM was the first operon found in 1993 with substantial homology to acrAB/TolC of E. coli conferring multiple antibiotic resistance, including quinolones such as nalidixic acid and ciprofloxacin in nalB mutants (Poole et al., 1993). MexAB-OprM has been reported to play a main role in conferring intrinsic resistance to several antibiotics, including quinolones, due to its constitutive expression (Li et al., 1995). It extrudes a wide range of diverse unrelated antibiotics: quinolones, macrolides, tetracyclines, lincomycin, chloramphenicol, novobiocin and β-lactams (except imipenem) to be pumped out (Vila and Martínez, 2008), (ii) mexCD-oprJ was described in 1996 as the efflux pump whose overexpression was responsible for the nfxB-type MAR phenotype (Poole et al., 1996a), (iii) in 1997, mexEF-oprN was shown to confer antibiotic resistance in nfxC-type mutants (Kohler et al., 1997, 1999), (iv) mexXY was studied in E. coli in 1999 for its ability to cause antibiotic resistance in conjunction with TolC or OprM (Mine et al., 1999), (v) mexJK was characterized in 2002 (Chuanchuen et al., 2002), (vi) mexHl-opmD was reported for its MAR-associated phenotype in 2003 (Sekiya et al., 2003), (vii) mexVW was found in 2003 and could be selected for its overexpression in MAR mutants (Li et al., 2003), (viii) mexPQ-opmE, and (ix) mexMN in 2005 revealed the two latest RND efflux pumps characterized to date (Mima et al., 2005). A great number of these efflux pumps are composed by a three-gene operon (mexAB-oprM, mexCD-oprJ, mexEF-oprN, mexHl-opmD and mexPQ-opmE), being the first gene the MFP, the second one the efflux protein, and the third gene the outer membrane protein. The other four pumps are just a common two-gene operon (mexXY, mexJK, mexVW and mexMN). Despite the lack of a final gene encoding for a porin, it does not mean that it is not needed. In fact, all these four pumps can work together with OprM (Mine et al., 1999; Chuanchuen et al., 2002; Li et al., 2003; Mima et al., 2005) or even with a hitherto uncharacterized porin (Chuanchuen et al., 2002; Li et al., 2003). This may be why a promoter-like sequence has been found upstream from the oprM gene permitting weak expression to ensure the functioning of the other two-gene efflux pumps in the case that MexAB is not functional (Zhao et al., 1998; Masuda et al., 2000). However, not all these pumps are able to extrude quinolones; there are two exceptions: MexJK-OprM (Chuanchuen et al., 2002) and MexMN-OprM (Mima et al., 2005), although in latter case is doubtful due to a low level of expression of the pump. All these operons have their own promoter in the upstream region, and in some cases the presence of a regulatory gene upstream from the promoter has been
demonstrated. MexR is transcribed divergently from mexAB and acts as a local repressor for this operon by binding to the promoter (Poole et al., 1996b). Two new ORFs have recently been characterized as additional repressors of the pump. The naiC gene is a member of the TetR/AcrR family located upstream from a two-gene operon. It has been suggested that the resulting proteins of this operon may modulate MexR levels and cause an indirect negative effect over the mexAB-oprM genes (Cao et al., 2004). NaID is another member of the TetR/AcrR family, which binds to a second promoter of the mexAB-oprM operon, causing a repressor effect by a direct mechanism, such as MexR (Sobel et al., 2005a; Morita et al., 2006). Overexpression of this pump has been implicated in the acquisition of quinolone resistance among clinical isolates, and several studies have reported a link between the presence of mutations in any of the regulatory loci and an increase in MexAB-OprM (Oh et al., 2003; Llanes et al., 2004; Henrichfreise et al., 2007).

MexCD-OprJ, the second efflux pump characterized, does not seem to be expressed during growth under laboratory conditions, thus no role in intrinsic resistance has been related to it (Poole et al., 1996a; Li et al., 2000). Upstream from this operon, an ORF, nfxB, transcribed divergently has been reported to encode a repressor protein of the pump (Poole et al., 1996a). The overexpression of the mexCD-oprJ operon confers extrusion ability regarding quinolones, macrolides, lincomycin, novobiocin, penicillins (except carbenicillin and sulbenicillin), cephamems (except ceftazidime), floromoxef and meropenem, and with lower specificity tetracyclines and chloramphenicol (Vila and Martínez, 2008). This phenotype appears in clinical strains as a consequence of mutations within nfxB gene, with two amino acid changes: Asp-56–Gly and Ala-124–Glu, being the most frequently found (Higgins et al., 2003; Henrichfreise et al., 2007). However, some cases have reported high levels of MexCD-OprJ not linked with a mutation in nfxB (Oh et al., 2003). Interestingly, P. aeruginosa clinical strains isolated from cystic fibrosis patients, which have evolved to a quinolone-resistant phenotype, show MexCD-OprJ overexpression as a predominant mechanism (Jalal et al., 2000). Alternatively, increased levels of this pump have also been shown to appear owing to inactivation of the mexAB-oprM genes, in an attempt to compensate for the loss of the main efflux pump activity. However, in this situation, the levels produced are not as high as those reached by a mutation within nfxB; thus the final phenotype shows higher susceptibility levels to all antibiotics in comparison with strains that have a functional MexAB-OprM (Li et al., 2000). Following this inverse correlation, the MexAB-OprM levels decrease when MexCD-OprJ is overexpressed (Li et al., 2000).

MexEF-OprN is the third most relevant efflux pump described to date with regard to quinolone resistance. This efflux pump, which can extrude fluoroquinolones, chloramphenicol, trimethoprim and tetracyclines (Vila and Martínez, 2008), has a particular genetic structure: upstream from the mexE there is no repressor gene transcribed divergently, but there is an ORF, called mexT, encoding a protein, which belongs to the LysR family of transcriptional activators, and is transcribed in the same direction as the other three genes. MexT is essential for the mexEF-oprN activation (Kohler et al., 1999). In addition, adjacent to and activated by mexT is a further gene, transcribed divergently, termed mexS [previously qrh (Kohler et al., 1999)], which does encode a regulatory protein, as it is, in fact, an oxidoreductase, but can confer the MAR phenotype by enhancement of MexEF-OprN overexpression (Sobel et al., 2005b). The mexEF-oprN is not expressed under standard growth in laboratory conditions. Moreover, its expression is not activated in the presence of the antibiotics susceptible to be pumped out (Kohler et al., 1999). However, wild-type strains can show a diverse degree of expression in basal conditions (Li et al., 2000). The operon can be activated by either a mutation in mexT (Maseda et al., 2000) or a mutation in mexS (Sobel et al., 2005b; Henrichfreise et al., 2007). Similar to what occurs with MexCD-OprJ, MexEF-OprN overexpression is also a predominant mechanism in P. aeruginosa clinical strains that have been isolated from cystic fibrosis patients with a quinolone-resistance phenotype. In addition, it is possible to find both pumps overexpressed at the same time (Jalal et al., 2000).

The first two-gene operon characterized was mexXY. The substrate specificity of this pump relies on exporting quinolones, macrolides, tetracyclines, lincomycin, chloramphenicol, aminoglycosides, penicillins (except carbenicillin and sulbenicillin), cephamems (except cefsulodin and ceftazidime) and meropenem (Vila and Martínez, 2008). Upstream from mexX, an adjacent gene, mexZ, has been characterized, which is transcribed in the opposite direction and encodes a member of the TetR/AcrR family (Ramos et al., 2005). MexZ is a repressor protein that binds to the pump promoter and inhibits MexXY expression. In contrast with the other members of this family, MexZ does not interact with the respective multidrug transporter substrate to turn on the corresponding operon, although it is known that drugs activate the efflux pump (Matsumoto et al., 2004). An implication in contributing to intrinsic resistance has been reported, although no significant role in extruding quinolones has been shown in wild-type strains (Masuda et al., 2000). The prevalence of overexpression in MexXY can be important as it is found as an efflux pump mechanism implicated in conferring the quinolone-resistance phenotype among clinical P. aeruginosa isolates (Oh et al., 2003). Some studies have
revealed that this pump can be activated in a great percentage of the clinical isolates studied (Llanes et al., 2004; Henrichfreise et al., 2007), and characterization of the mexZ gene mutations appears to be the genetic variation responsible for the overexpression. In addition, it has been suggested that an interplay between the different efflux pumps may take place (Li et al., 2000; Sobel et al., 2005b).

The mexHl-opmD and mexPQ-opmE are the two other three-gene operons currently described in P. aeruginosa. When overexpressed ‘in vitro’, MexHl-Opmdm can extrude norfloxacin, nalidixic acid, kanamycin, spectinomycin, carbenicillin, tetracycline, chloramphenicol and rifampicin (Sekiya et al., 2003), whereas MexPQ-Opme confers resistance to quinolones, tetracycline, erythromycin, kitasamycin, rokitamycin and chloramphenicol (Vila and Martínez, 2008). The three other remaining two-gene operons, mexJK, mexVW and mexMN, work in conjunction with OprM, but only MexVW has been reported to confer quinolone resistance in ‘in vitro’ assays, as well as tetracycline, chloramphenicol and erythromycin (Vila and Martínez, 2008); whereas MexJK only extrudes erythromycin and tetracycline, and MexMN chloramphenicol and thiamphenicol (Vila and Martínez, 2008). To date, none of these five pumps has a known ORF encoding a regulatory protein of the operon, and no constitutive expression in basal growth or implication in conferring quinolone-resistance phenotype by means of its overexpression has been detected.

- Acinetobacter baumannii. The intrinsic resistance in A. baumannii that let it become the paradigm of multiresistant bacteria has been attributed to low number and size of the porins simultaneously with low-level constitutive expression of efflux pump(s). The main porin contributing to intrinsic resistance characterized so far has been HMP-AB, a homologue of OmpA from Enterobacteriaceae and OprFr from P. aeruginosa (Vila et al., 2007). The first efflux pump characterized was found to be encoded in the adeABC operon, which encodes three consecutive proteins (AdeA, AdeB and AdeC) forming an RND efflux pump (Table 5), showing homology with the three-gene operons described in P. aeruginosa. The substrates susceptible to extrusion are: aminoglycosides, tetracyclines, fluoroquinolones, erythromycin, chloramphenicol, trimetoprim and cefotaxime (Magnet et al., 2001). The essential role for efflux functioning does not seem to be equally played by every member of the pump, as inactivation of adeB leads to a decreased MIC to all these antimicrobial agents, whereas the inactivation of adeC does not seem to have any consequence in the MAR phenotype, meaning that AdeC can be replaced by another porin (Magnet et al., 2001; Marchand et al., 2004). Expression of the adeABC operon is regulated by the adeRS, a two-component regulatory system which is co-transcribed in the opposite direction (Koretke et al., 2000). Gentamicin-resistant strains acquired ‘in vitro’ showing a MAR phenotype were studied and two different kinds of mutations appeared: in the amino acid codon a Thr-1533→Met in AdeS and in the amino acid codon Pro-1163→Leu in AdeR. These results have suggested that MAR phenotype appears as a consequence of adeABC overexpression, which in turn may be a response when mutations in the regulatory loci are present (Marchand et al., 2004). The clinical implication of the overexpression of this pump was shown as strains recovered from two different outbreaks. In one group, MAR mutants showed a high level of expression of adeABC genes; while in the second group, the MAR phenotype was not linked with this efflux pump overexpression (Higgins et al., 2004).

adeIJK is the second RND efflux pump characterized in A. baumannii (Table 5). It extrudes β-lactams, chloramphenicol, tetracyclines, erythromycin, fluoroquinolones, trimetoprim, fusidic acid, novobiocin, lincomasides and rifampin. It has not been possible to clone these genes in plasmids probably because expression is toxic. This pump is found in all laboratory and clinical isolates, as well as the corresponding homologues in the other Acinetobacter species, implying a potential role in intrinsic resistance (Damier-Piolle et al., 2008). AbeM is another efflux pump characterized in A. baumannii that belongs to the MATE superfamily, which shows high homology with YdhE of E. coli. The substrates susceptible to be pumped out with this efflux pump are fluoroquinolones and gentamicin, whereas those with lower affinity include kanamycin, erythromycin, chloramphenicol and trimetoprim. No clinical data are available at present (Su et al., 2005).

- Stenotrophomonas maltophilia. In this group of microorganisms Stenotrophomonas maltophilia need special attention because quinolone resistance acquisition is not related to mutations in the gyrA and/or parC genes (Ribera et al., 2002a; Valdezate et al., 2002). Quinolone resistance is acquired by high efficiency of efflux pumps, which reduces intracellular quinolone concentrations to a level at which the quinolone targets are no longer challenge (Ribera et al., 2002b; Valdezate et al., 2005) (Table 2). Up today, two efflux systems have been identified in this pathogen (Table 5): SmeDEF (Alonso and Martínez, 2000) and SmeABC (Li et al., 2002).

Studies of the prevalence of smeDEF and smeABC overexpression have been carried out. It has been shown that smeDEF overexpression may occur in approximately 32% of the clinical isolates tested (Alonso and Martínez, 2001; Chang et al., 2004) whereas smeABC overexpression can be found in 59% (Chang et al., 2004). Both overexpressions are related to quinolone-resistant strains.
Microorganisms lacking Topo IV. Campylobacter jejuni, Corynebacterium spp., Helicobacter pylori and other microorganisms lack Topo IV. In these microorganisms a single mutation in the gyrA gene produces a high level of resistance to ciprofloxacin whereas a double mutation in the gyrA gene is necessary to produce a high level of resistance to moxifloxacin (Ruiz et al., 2005; Sierra et al., 2005a) (Table 3).

Although this species can become ciprofloxacin-resistant only with the acquisition of one point mutation in gyrA, efflux mechanisms have also been described. The main efflux pump found in C. jejuni was dubbed CmeABC. This system can export fluoroquinolones, erythromycin, rifampin, tetracycline, chloramphenicol, β-lactams and ethidium bromide (Lin et al., 2002). Its levels of expression have not only been detected in wild-type strains but also in both kinds of MAR mutants, those selected ‘in vitro’ by exposure to the antibiotic and clinical isolates. These results suggest that this efflux pump plays a role in intrinsic resistance to the antibiotics that can be transported due to its constitutive expression, as well as in conferring high levels of fluoroquinolone resistance (Luo et al., 2003; Lin et al., 2005). In addition, the inactivation of this pump leads to an increase in the susceptibility to fluoroquinolones in wild-type strains (Lin et al., 2002) and decreases the resistance phenotype below the clinical break points in resistant strains (Luo et al., 2003). Among clinical isolates it is possible to find several situations: (i) strains that show the maximum levels of ciprofloxacin resistance as a consequence of cmeB overexpression in addition to a gyrA mutation (64–128 mg l\(^{-1}\)), (ii) only a gyrA mutation (8–64 mg l\(^{-1}\)), (iii) only cmeB overexpression (2–32 mg l\(^{-1}\)), and (iv) MAR phenotype not affecting ciprofloxacin, so that there is no gyrA mutation and no cmeB overexpression (0.25–0.5 mg l\(^{-1}\)) (Pumbwe et al., 2004). The CmeR regulates the cmeABC expression. This repressor belongs to the TetR/AcrR family of regulators (Ramos et al., 2005). Mutations affecting the normal function of this local repressor have also been shown in the substrate binding region (Pumbwe et al., 2004) and in the cmeABC promoter (Lin et al., 2005).

A second RND efflux system encoded by cmeDEF contributes to the intrinsic resistance in C. jejuni (Akiba et al., 2006). However, its overexpression in C. jejuni clinical isolates does not contribute to the ciprofloxacin efflux (Pumbwe et al., 2004; Ge et al., 2005).

Gram-positive bacteria. The first mutation associated with fluoroquinolone resistance in S. aureus is usually found in the parC gene (grlA gene in this microorganism) (Table 4), hence Topo IV is considered the primary target for fluoroquinolones. A mutation at the amino acid codon Ser-80 (changing to Phe) of the grlA gene produces a MIC of norfloxacin of 4 mg l\(^{-1}\), whereas a double mutation at the amino acid codon Ser-80 of the grlA gene plus a mutation at the amino acid codon Ser-84 (changing to Leu) increases the MIC of norfloxacin to 16 mg l\(^{-1}\) and three mutations, two in the grlA gene and a third in the gyrA gene, generate a MIC of norfloxacin of 128 mg l\(^{-1}\) (Table 4) (Sierra et al., 2002). However, in Streptococcus pneumoniae the primary target can be both DNA gyrase and Topo IV, depending on the fluoroquinolone (Pan and

Table 2. The most frequent amino acid substitutions found in GyrA and ParC of non-fermentative Gram-negative bacilli.

| Microorganism                  | Amino acid change | MIC (mg l\(^{-1}\)) |
|--------------------------------|-------------------|---------------------|
|                                | GyrA              | ParC                |                  |
| Pseudomonas aeruginosa wt      | Thr-83 Asp-87 Ser-80 Glu-84 |                     |
| G. corneum spp. Ile            |                   | 2                   |
| G. corneum spp. Ile            |                   | 8                   |
| G. corneum spp. Ile            |                   | 32                  |
| G. corneum spp. Ile            |                   | 128                 |
| Acinetobacter baumannii wt     | Ser-83 Asp-87 Ser-80 Glu-84 |                     |
| G. corneum spp. Leu            |                   | 4–64                |
| G. corneum spp. Leu            |                   | 32–128              |

MIC, minimum inhibitory concentration; CIP, ciprofloxacin.

Table 3. The most amino acid substitutions found in GyrA and ParC of different microorganisms lacking topoisomerase IV.

| Microorganism                  | Amino acid change | MIC (mg l\(^{-1}\)) |
|--------------------------------|-------------------|---------------------|
|                                | GyrA              | CIP                 | MOX |
| Campylobacter spp.              |                   |                     |
| Campylobacter jejuni            | Thr-86 Asp-90 Ile | > 32 0.38–2         |
| Campylobacter jejuni            | Asn Ile           | > 32 0.38–2         |
| Campylobacter jejuni            |                   |                     |
| Corynebacterium spp.            | Ser-87 Asp-91 Phe | 1 0.19              |
| Corynebacterium jejuni          | Tyr Phe           | 3 0.5               |
| Corynebacterium jejuni          | Ala Phe           | > 32 6              |

CIP, ciprofloxacin; MIC, minimum inhibitory concentration; MOX, moxifloxacin.
Fisher, 1999; Sierra et al., 2005b). In addition to point mutations in the genes encoding the protein targets, acquisition resistance by intra- or interspecific recombination has been shown (Balsalobre et al., 2003; de la Campa et al., 2004; Stanhope et al., 2005). However, in clinical isolates point mutations are more frequent than recombinant ones (Ferrándiz et al., 2000).

Drug efflux transporters of Gram-positive bacteria mainly belong to MFS superfamily, although members of SMR and ABC families have also been characterized. Furthermore, members of MATE family have also been observed although they were believed to exist only in Gram-negative bacteria (Poole, 2000b).

- **Staphylococcus aureus.** The first efflux pump characterized from a norfloxacin-resistant clinical strain was NorA (Table 5), a member of the MFS superfamily that when overexpressed from a plasmid yielded a higher MIC for norfloxacin and ciprofloxacin. The role of NorA in quinolone-susceptible strains became clear after its inactivation, as the resulting strain showed an eightfold decrease in the MIC of norfloxacin in addition to a threefold increase of the same antibiotic internal accumulation (Yamada et al., 1997). The mechanisms by which norA is overexpressed in clinical isolates have been reported. The first mutation identified linked to this phenotype was a mutation in the norA promoter most likely resulting in prevention of repressor binding (Ng et al., 1994). In other cases high levels of NorA resulted from increased stability of its mRNA (Fournier et al., 2001; Kaatz et al., 2005b). Increased levels of NorA were also linked to the two-component regulatory system ArlSR (Koretke et al., 2000). Inactivation of ArlS resulted in an increase in NorA production (Fournier et al., 2000). The third option is the presence of a transcriptional regulator, MgrA (formerly NorR), which has been shown to bind specifically to the norA promoter. It was previously assumed to play a positive role in norA expression (Truong-Bolduc et al., 2003); however, a new study has shown that in fact this regulator causes a negative effect on NorA levels, suggesting that the first role as an activator could be due to high levels of the MgrA protein (Kaatz et al., 2005b). Recently, another regulator, dubbed NorG, has been proposed. This protein is able to bind to its own promoter, meaning that it can be autoregulated, and to norA promoter although it has not resulted in any increase in norA transcripts. Intriguingly it cannot bind to mgrA promoter, whereas MgrA can bind to norG promoter, indicating that MgrA may play a more global effect than NorG does (Truong-Bolduc and Hooper, 2007).

Table 4. Amino acid substitutions found in GyrA and ParC of different Gram-positive cocci.

| Microorganism               | Amino acid change | MIC (mg l⁻¹) NOR |
|-----------------------------|-------------------|-----------------|
| **Staphylococcus aureus wt**| Ser-84 Asp-88     | Ser-80 Glu-84   |
|                            | Leu               | Phe             |
|                            | Leu               | Phe             |
|                            |                   | Phe             |
|                            |                   | Lys             |
| **Streptococcus pneumoniae wt**| Ser-83 Asp-87     | Ser-79 App-83   |
|                            | Tyr               | Tyr             |
|                            |                   | Tyr             |
|                            |                   | 8               |
|                            |                   | 64              |
|                            |                  |                 |
| MIC, minimum inhibitory concentration; NOR, norfloxacin.

Table 5. Fluoroquinolone efflux transporters characterized to date and their clinical implication.

| Microorganism             | Efflux pumps that can extrude fluoroquinolones in a reproducible mannera |
|---------------------------|--------------------------------------------------------------------------|
| Acinetobacter baumannii   | AdeABC, AdeJK, AbeM                                                     |
| Campylobacter jejuni      | CmeABC, CmeDEF                                                           |
| Escherichia coli          | AcrAB, AcrEF, YdhE                                                       |
| Klebsiella pneumoniae     | KmrA, KdeA, PmpM                                                         |
| Pseudomonas aeruginosa    | MfdA                                                                     |
| Salmonella enterica       | MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY, MexVW, MexHI-OpmD, MexPQ-OpmD |
| Serratia marcescens       | SmeDEF, SmeABC                                                           |
| Staphylococcus aureus     | NorA, NorB, NorC, SdrM, MepA                                              |
| Streptococcus pneumoniae  | PmrA, PatA, PatB                                                          |

a. Boldface type indicates those efflux pumps found overexpressed in fluoroquinolone-resistant clinical isolates.

© 2008 The Authors
Journal compilation © 2008 Society for Applied Microbiology and Blackwell Publishing Ltd, *Microbial Biotechnology*, 2, 40–61
Alternatively, other pumps have been described with ability of extruding quinolones. This can be the case of NorB, NorC, MepR and SdrM (Table 5). NorB is a member of the MFS superfamily and pumps out norfloxacin and ciprofloxacin as NorA does, but in addition it can recognize moxifloxacin and sparfloxacin as substrates, causing, when overexpressed, an eightfold increase in the MICs of the first two antibiotics and a fourfold increase in the others. It has been reported a low-level expression in wild-type strains suggesting that it may play a role in determining susceptibilities in quinole-susceptible strains as NorA does (Truong-Bolduc et al., 2005). This pump is negatively regulated by MgrA, which binds directly to the norB promoter which contains less binding motifs than those found in norA promoter resulting in a weaker interaction (Truong-Bolduc et al., 2005). In addition, NorG has been shown to bind directly to norB promoter and cause a positive effect by increasing norB transcripts. However, inactivation of norG in a wild-type strain does not lead to any change in the MIC of fluoroquinolones (Truong-Bolduc and Hooper, 2007).

NorC is another MFS member and shows substantial homology with NorB protein. Its overexpression causes a fourfold increase in the MIC of norfloxacin and moxifloxacin and reproducible twofold increase in the MIC of ciprofloxacin and sparfloxacin, resulting in the same substrate profile as NorB. Its regulation is based on the negative effect that MgrA causes over its transcription (Truong-Bolduc et al., 2006).

The overproduction of the MFS SdrM leads to a twofold increase in the MIC of norfloxacin. No basal expression has been detected in standard laboratory conditions suggesting that activation must occur in order to detect it. No clear role of MgrA on SdrM expression has been reported (Yamada et al., 2006).

The last efflux pump is a MATE superfamily member called MepA (Table 5). This protein is encoded within a three-gene operon mepRAB. The first gene encodes for a transcriptional regulator with strong homology with MarR, which acts as a repressor of its own transcription and MepA expression. The second gene encodes the efflux pump, while the third gene codifies for a protein with no homology to any protein with known function. Two ‘in vitro’ selected fluoroquinolone-resistant mutants overexpressed this pump as a consequence of mutations within the mepR-encoding region in one case, leading to a truncated protein and a consequent lack of repressor activity; however, no detectable nucleotide mutation was found in the operon of the second strain, suggesting that another regulatory loci must be implicated in conferring increased levels of this pump. In both mutant strains mepR and mepRAB transcripts can be detected (Kaatz et al., 2005a).

There are few reports about the prevalence of the overexpression of these efflux pumps in clinical isolates. A recent report has analysed the prevalence of all known efflux pumps (with exception of SdrM) and suggests that around 50% of the clinical strains evaluated had at least one efflux system implicated in quinolone resistance. Increased expression of NorA and NorB were the most predominant mechanisms, although overexpression of NorC and MepA were also observed. The concomitant overproduction of several pumps (20% of the effluxing strains) was also described, being the increased levels of NorB and NorC what predominated. Mutations such as point mutations, insertions or deletions, in mepR, norA, norB and norC promoters, were described in overexpressing strains respectively. In addition, mutations in structural genes, such as those mutations leading to a MepR-truncated protein, were also found. However no mutation affecting MgrA protein levels was seen (DeMarco et al., 2007).

- Streptococcus pneumoniae. Efflux pump as a mechanism of fluoroquinolone resistance in S. pneumoniae is not well elucidated. To date, only two efflux pumps have been characterized (Table 5). The first one is PmrA, a protein belonging to the MFS superfamily showing substantial homology with NorA, and whose overexpression leads to an increase in the MIC of norfloxacin and ciprofloxacin which can decrease up to fourfold upon reserpine addition. Furthermore, ethidium bromide accumulation is decreased in the strain that overexpresses this efflux system but it totally reverts to wild-type levels when pmrA has been inactivated, suggesting its role as an efflux system (Gill et al., 1999). Its prevalence among clinical isolates has been reported; however, a clear role has not been elucidated as it shows variable levels of expression among norfloxacin-resistant and -susceptible strains, as well as resistant strains do not always show a phenotype affected by reserpine. In general, it appears in addition to QRDR mutations and it is not well associated with strains showing a high level of norfloxacin resistance. Furthermore, susceptible strains showing increased levels of PmrA without an effect of reserpine have been found (Piddock et al., 2002).

Its basal expression in laboratory strains and fluoroquinolone-susceptible clinical isolates let think about a possible role in determining the intrinsic susceptibilities of these agents in standard conditions (without drug exposure). However, its role in acquiring fluoroquinolone resistance can be limited (Piddock et al., 2002; Avrain et al., 2007).

The second efflux system characterized is that formed by two ABC transporters, PatA and PatB. Yet, it is not clear if they could interact so as to constitute a heterodimeric efflux system as it happens in other Gram-positive bacteria, or maybe they are two independent systems that both contribute to the final multidrug-resistance phenotype. Its
overexpression has only been found in resistant mutants, where its inactivation has led to a loss of multidrug-resistance phenotype. However, reserpine only seems to inhibit PatA contribution to resistance, whereas PatB would not be affected. Intriguingly, when patA has been inactivated, an increase in patB expression occurs, but not vice versa (Marrer et al., 2006; Avrain et al., 2007; Garvey and Piddock, 2008). Among clinical isolates high levels of both PatA and PatB have been found as a mechanism of resistance, instead of PmrA overexpression, around 25% of the isolates evaluated (Garvey and Piddock, 2008). Currently, it is thought that maybe PmrA is not the main efflux system characterized, as it seems that overexpression of PatA/B is more prevalent among clinical isolates. However other systems could be implicated and not necessarily reserpine-susceptible.

**Plasmid-mediated quinolone resistance**

In 1998, the first plasmid-mediated mechanism of resistance to quinolones was described in *K. pneumoniae* (Martínez-Martínez et al., 1998). This was due to the *qnrA* gene, which encodes for a pentapeptide repeat protein (Tran and Jacoby, 2002; Tran et al., 2005a,b). As expected from its structure, Qnr determinants did not seem to produce a change in intracellular quinolone accumulation nor did it cause drug inactivation. The direct effects of the Qnr have been studied using DNA-supercoiling assays. At least when performed ‘in vitro’, Qnr protects the DNA gyrase from the inhibition of ciprofloxacin. This protection is dependent on Qnr concentration and is inversely proportional to ciprofloxacin concentrations (Tran et al., 2005a). Moreover, Topo IV, the secondary target of quinolones in *Enterobacteriaceae*, also seems to be protected from quinolones by Qnr.

However, the expression of the Qnr peptide results in low-level quinolone resistance. Since the first report of this mechanism of resistance to quinolones, a large number of studies addressed to find this gene in different collections of clinical isolates have been reported. Up to the present, three *qnr* genes have been identified: the *qnrA* gene found in *K. pneumoniae*, and later found in other *Enterobacteriaceae*, *qnrS*, first described in *Shigella flexneri* (Hata et al., 2005) and the *qnrB* gene located on plasmids found in *K. pneumoniae*, *Citrobacter koseri*, *E. cloacae* and *E. coli* (Jacoby et al., 2003).

After the first prevalence survey of the *qnrA* gene in 350 Gram-negative isolates in which this gene was not found (Jacoby et al., 2003), several reports suggested that this plasmid was widely distributed and was present in all clinically relevant *Enterobacteriaceae* (Wang et al., 2003; 2004; Cheung et al., 2005; Jeong et al., 2005; Jonas et al., 2005; Mammeri et al., 2005; Nazik et al., 2005; Robicsek et al., 2005). Although these genes have not been found in non-fermenting Gram-negative bacilli such as *P. aeruginosa* and *A. baumannii*, it is important to point out that the *qnrS* gene has been found in *Aeromonas* spp. isolated from both environment and clinical samples (Cattoir et al., 2008; Sánchez-Césedes et al., 2008).

The *qnrA* gene has recently been identified in the chromosome of the water-borne species *Shewanella algaee* (Poirel et al., 2005a). The G+C content of the *qnrA*-like gene of *S. algeae* matches that of the genome exactly, suggesting that this microorganism may be the origin of the *qnrA* gene. Moreover, *Vibrionaceae* may also constitute a reservoir for Qnr-like quinolone-resistance determinants (Poirel et al., 2005b). However, a *qnr*-like gene has recently been found in *Enterococcus faecalis*, suggesting that the expression of this gene may explain the intrinsic resistance of *E. faecalis* to fluoroquinolones (Arsène et al., 2007).

If Qnr is the only mechanism of resistance to quinolones present, the MIC of ciprofloxacin will increase only to 0.25 mg l\(^{-1}\), hence being considered susceptible. Although the action of Qnr results in low-level quinolone resistance, this reduced susceptibility facilitates the selection of mutants with higher-level resistance (Martínez-Martínez et al., 1998). It is thought that this low level of resistance to the antibacterial agent makes it possible for bacteria populations to raise concentrations that facilitate the occurrence of secondary mutations and thus the high level of resistance.

Recently, a new mechanism of transferable quinolone resistance has been reported: enzymatic inactivation of certain quinolones. The *cr* variant of *aac(6\(^{-}\))-Ib-cr encodes an aminoglycoside acetyltransferase that confers reduced susceptibility to ciprofloxacin by N-acetylation of its piperazinyl amine (Robicsek et al., 2006). *Aac(6\(^{-}\))-Ib-cr* has two amino acid changes, Thr-102→Arg and Asp-179→Tyr, which together are necessary and sufficient for the ability of the enzyme to acetylate ciprofloxacin. The *aac(6\(^{-}\))-Ib* gene encodes a common aminoglycoside acetyltransferase responsible for resistance to the aminoglycosides such as kanamycin, amikacin and tobramycin. A plasmid containing this new variant of *aac(6\(^{-}\))-Ib* was cloned resulting in MICs to kanamycin of 64 μg/ml, as expected, and a three- to fourfold increase in the MIC of ciprofloxacin in *E. coli* DH110B. This new variant was then called *aac(6\(^{-}\))-Ib-cr* for ciprofloxacin resistance (Robicsek et al., 2006). Not only Aac(6\(^{-}\))-Ib-cr has been described to cause low-level ciprofloxacin resistance, but it also acts additively together with Qnr to generate ciprofloxacin resistance. In fact, when both *qnrA* and *aac(6\(^{-}\))-Ib-cr* are present in the same bacteria, the level of resistance to ciprofloxacin is increased fourfold more than that conferred by *qnrA* alone, with a MIC of ciprofloxacin of 1.0 μg ml\(^{-1}\), a value near the clinical break point for susceptibility. In addition, the presence of *aac(6\(^{-}\))-Ib-cr* alone substantially increased the frequency of...
selection of chromosomal mutants upon exposure to ciprofloxacin. Moreover, the aac(6′)-Ib-cr gene has also been frequently located in the same genetic element as the blaCTX-M gene (Pitout et al., 2008). Park and colleagues (2006), on analysing 31 Enterobacteriaceae with a MIC of ciprofloxacin ≥ 0.25 mg l−1, found that 14% carried the aac(6′)-Ib-cr gene.

A new plasmid-mediated quinolone-resistance mechanism has recently been described (Yamane et al., 2007). This new mechanism consists of a gene named qepA that encodes for an efflux pump. QepA showed high similarity with members of the Major Facilitator Superfamily responsible for resistance to hydrophilic quinolones such as norfloxacin and ciprofloxacin. This gene is located in a 10 kb region flanked by two copies of IS

References
Abouzeed, Y.M., Baucheron, S., and Cloeckaert, A. (2008) ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 52: 2428–2434.

Acknowledgements
This work was supported by the Ministry of Health, Spain (FIS 05/0068), MCYT-FEDER (BIO2005/00295 and PETRI 1995-0957-OP) and the Generalitat de Catalunya (XeRBa, 2005SSGR-00444 and 2005SER-00663). This work was also supported by Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III-FEDER, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008).

Alonso, A., and Martinez, J.L. (2001) Expression of multidrug efflux pump smeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 45: 1879–1881.

Amabile, C.F., and Demple, B. (1991) Molecular characterization of the soxRS genes of Escherichia coli: two genes control a superoxide stress regulon. Nucleic Acids Res 19: 4479–4484.

Ariza, R.R., Li, Z., Ringstad, N., and Demple, B. (1995) Activation of multiple antibiotic resistance and binding of stress-inducible promoters by Escherichia coli Rob protein. J Bacteriol 177: 1655–1661.

Arsène, S., and Leclerc, R. (2007) Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. Antimicrob Agents Chemother 51: 3254–3258.

Avrain, L., Garvey, M., Mesaros, N., Glupczynski, Y., Mingeot-Leclerq, M.P., Piddock, L.J.V., et al. (2007) Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations. J Antimicrob Chemother 60: 965–972.

Ball, P. (1998) The quinolones: history and overview. In The Quinolones, 2nd edn. Andriole, V.T. (ed.). San Diego, CA, USA: Academic Press, pp. 1–28.

Ball, P. (2000) Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46: 17–24.

Ball, P., Fernald, A., and Tillotson, G. (1998) Therapeutic advances of new fluoroquinolones. Exp Opin Invest Drugs 7: 761–783.

Balsalobre, L., Ferrándiz, M.J., Liñares, J., Tubau, F., and de la Camoa, A.G. (2003) Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 47: 2072–2081.

Barrett, J.F. (2000) Moxifloxacin Bayer. Curr Opin Invest Drugs 1: 45–51.

Baucheron, S., Tyler, S., Boyd, D., Mulvey, M.R., Chaslus-Dancla, E., and Cloeckaert, A. (2004) AcrAB-ToIC directs efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium DT104. Antimicrob Agents Chemother 48: 3729–3735.

Blanchard, Y., and Cloeckaert, A. (2004) AcrAB-TolC directs efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium DT104. Antimicrob Agents Chemother 48: 3729–3735.

Bhavnani, S.M., and Ballow, C.H. (2000) New agents for Gram-positive bacteria. Curr Opin Microbiol 3: 528–534.

Boehringer, M., and Daille, F. (1997) Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 43: 180–181.
Mechanism of action of and resistance to quinolones

Champoux, J.J. (2001) DNA topoisomerases: structure, function, and mechanism. *Annu Rev Biochem* 70: 369–413.

Chang, L.L., Chen, H.F., Chang, C.Y., Lee, T.M., and Wu, W.J. (2004) Contribution of integrons, SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of *Stenotrophomonas maltophilia*. *J Antimicrob Chemother* 53: 518–521.

Chen, S., Zhang, A., Blyn, L.B., and Storoz, G. (2004) MicC, a second small-RNA regulator of Omp protein expression in *Escherichia coli*. *J Bacteriol* 186: 6689–6697.

Chen, S., Cui, S., McDermott, P.F., Zhao, S., White, D.G., Paulsen, I., and Meng, J. (2007) Contribution of target gene mutations and efflux to decreased susceptibility of *Salmonella enterica* serovar Typhimurium to fluoroquinolones and other antimicrobials. *Antimicrob Agents Chemother* 51: 535–542.

Chenia, H.Y., Pillay, B., and Pillay, D. (2006) Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. *J Antimicrob Chemother* 58: 1274–1278.

Cheung, T.K., Chu, Y.W., Chu, M.Y., Ma, C.H., Yung, R.W., and Kam, K.M. (2005) Plasmid-mediated resistance to ciprofloxacin and ceftaxime in clinical isolates of *Salmonella enterica* serotype enteritidis in Hong Kong. *J Antimicrob Chemother* 56: 586–589.

Chou, J.H., Greenberg, J.T., and Demple, B. (1993) Posttranscriptional repression of *Escherichia coli* OmpF protein in response to redox stress: positive control of the mcrC antisense RNA by the soxRS locus. *J Bacteriol* 175: 1026–1031.

Chu, C., Su, L.H., Chu, C.H., Baucherion, S., Cloeckaert, A., and Chiu, C.H. (2005) Resistance to fluoroquinolones linked to gyrA and parC mutations and overexpression of acrAB efflux pump in *Salmonella enterica* serotype Choleraesuis. *Microb Drug Resist* 11: 248–253.

Chu, D.T.W. (1996) The future role of quinolones. *Exp Opin Ther Patents* 6: 711–737.

Chuanchuen, R., Narasaki, C.T., and Schweizer, H.P. (2002) The MexJK efflux pump of *Pseudomonas aeruginosa* requires OprM for antibiotic efflux but not for efflux of triclosan. *J Bacteriol* 184: 5036–5044.

Cohen, S.P., McMurray, L.M., and Levy, S.B. (1988) marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of *Escherichia coli*. *J Bacteriol* 170: 5416–5422.

Cohen, S.P., McMurray, L.M., Hooper, D.C., Wolfson, J.S., and Levy, S.B. (1989) Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) *Escherichia coli* selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. *Antimicrob Agents Chemother* 33: 1318–1325.

Corbett, K.D., and Berger, J.M. (2004) Structure, molecular mechanisms and evolutionary relationships in DNA topoisomerases. *Annu Rev Biophys Biomol Struct* 33: 95–118.

Corbett, K.D., Shultzaberger, R.K., and Berger, J.M. (2004) The C-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold. *Proc Natl Acad Sci USA* 101: 7289–7298.

© 2008 The Authors
Journal compilation © 2008 Society for Applied Microbiology and Blackwell Publishing Ltd, *Microbial Biotechnology*, 2, 40–61
efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 42: 2701–2706.

Hata, M., Suzuki, M., Matsumoto, M., Takahashi, M., Sato, K., lbe, S., and Sakae, K. (2005) Cloning of a novel gene for quinolone resistance from a transferable plasmid in Shi- gella flexneri 2b. Antimicrob Agents Chemother 49: 801–803.

Henrichfreise, B., Wiegand, I., Pfister, W., and Wiedemann, B. (2007) Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 51: 4062–4070.

Hernández-Allés, S., Conejo, M.C., Pascula, A., Tomás, J.M., Benedi, V.J., and Martínez-Martínez, L. (2000) Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of Klebsiella pneumoniae. J Antimicrob Chemother 46: 273–277.

Hiasa, H. (2002) The Glu-84 of the parC subunit plays critical roles in both Topoisomerase IV-quinolone and Topo- isomerase IV–DNA interactions. Biochemistry 41: 11779–11785.

Hiasa, H., and Shea, M.E. (2000) DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase–quinolone–DNA ternary complex. J Biol Chem 275: 34780–34786.

Higgins, N.P., Peebles, C.L., Sugino, A., and Cozzarelli, N.R. (1978) Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity. Proc Natl Acad USA 75: 1773–1777.

Higgins, P.G., Fluit, A.C., Milatovic, D., Verhoef, J., and Schmitz, F.J. (2003) Mutations in GyrA, ParC, MexR and NxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 21: 409–413.

Higgins, P.G., Wisplinghoff, H., Stefanik, D., and Seifert, H. (2004) Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 54: 821–823.

Hiirai, K., Aoyama, H., Suzue, S., Irikura, T., Iyobe, S., and Mitsuhashi, S. (1986) Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother 30: 248–253.

Hu, X.E., Kim, N.K., Gray, J.L., Almstead, J.I.K., Seibel, W.L., and Ledoussal, B. (2003) Discovery of (3S)-Amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity against resistant pathogens. J Med Chem 46: 3655–3661.

Jacob, G.A. (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41: S120–S126.

Jacob, G.A., Chow, N., and Waites, K.B. (2003) Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 47: 559–562.

Jalal, S., Ciofu, O., Holby, N., Gotoh, N., and Wretlind, B. (2000) Molecular mechanisms of fluoroquinolone resis- tance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 44: 710–712.

Jellen-Ritter, A.S., and Kern, W.V. (2001) Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone. Antimicrob Agents Chemother 45: 1467–1472.

Jeong, J.Y., Yoon, H.J., and Kim, E.S. (2005) Detection of qnr in clinical isolates of Escherichia coli from Korea. Antimicrob Agents Chemother 49: 2522–2524.

Jonas, D., Biehler, K., Hartung, D., Spitzmuller, B., and Daschner, F.D. (2005) Plasmid-mediated quinolone resis- tance in isolates obtained in German intensive care units. Antimicrob Agents Chemother 49: 773–775.

Kaatz, G.W., McAleese, F., and Seo, S.M. (2005a) Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob Agents Chemother 49: 1857–1864.

Kaatz, G.W., Thyagarajan, R.V., and Seo, S.M. (2005b) Effect of promoter region mutations and mgra overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter. Antimicrob Agents Chemother 49: 161–169.

Kampranis, S.C., and Maxwell, A. (1996) Conversion of DNA gyrase into a conventional type II topoisomerase. Proc Natl Acad USA 93: 14416–14421.

Kampranis, S.C., Bates, A.D., and Maxwell, A. (1999) A model for the mechanism of strand passage by DNA gyrase. Proc Natl Acad USA 96: 8414–8419.

Kato, J.-I., Nishimura, Y., Imamura, R., Niki, H., Hiraga, S., and Suzuki, H. (1990) New topoisomerase essential for chromosome segregation in E. coli. Cell 63: 393–404.

Kern, W.V., Oethinger, M., Jellen-Ritter, A.S., and Levy, S.B. (2000) Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 44: 814–820.

Kim, O.K., and Ohemeng, K.A. (1998) Patents on DNA gyrase inhibitors: January 1995 to March 1998. Expert Opin Ther Pat 8: 959–969.

Kim, O.K., Barrett, J.F., and Ohemeng, K. (2001) Advances in DNA gyrase inhibitors. Exp Opin Invest Drugs 10: 199–212.

Klevan, L., and Wang, J.C. (1980) Deoxyribonucleic acid gyrase-deoxyribonucleic acid complex containing 140 base pairs of deoxyribonucleic acid and $\alpha_2\beta_2$ protein core. Biochemistry 19: 5229–5234.

Kohler, T., Michea-Hamzehpour, M., Henze, U., Gotoh, N., Curty, L.K., and Pechère, J.C. (1997) Characterization of MexE-MexF-OpnR, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 23: 345–354.

Kohler, T., Epp, S.F., Curty, L.K., and Pechère, J.C. (1999) Characterization of MexT, the regulator of the MexE-MexF-OpnR multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 181: 6300–6305.

Koretko, K.K., Lupas, A.N., Warren, P.V., Rosenberg, M., and Brown, J.R. (2000) Evolution of two-component signal transduction. Mol Biol Evol 17: 1956–1970.

Koutsoliotou, A., Martins, E.A., White, D.G., Levy, S.B., and Demple, B. (2001) A soxRS-consituitive mutation contributing to antibiotic resistance in a clinical isolate of Salmonella enterica (serovar Typhimurium). Antimicrob Agents Chemother 45: 38–43.

Koutsoliotou, A., Peria-Liopis, S., and Demple, B. (2005) Constitutive soxR mutations contribute to multiple-
antibiotic resistance in clinical Escherichia coli isolates. *Antimicrob Agents Chemother* **49**: 2746–2752.

Lesher, G.Y., Froelich, E.J., Gruett, M.D., Bailey, J.H., and Brundage, R.P. (1962) 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. *J Med Chem* **5**: 1063–1065.

Levine, C., Hiasa, H., and Marians, K.J. (1998) DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. *Biochim Biophys Acta-Genet Struct Expr* **1400**: 29–43.

Li, X.Z., Barré, N., and Poole, K. (1995) Role of MexA-MexB-OprM in antibiotic efflux in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **39**: 1948–1953.

Li, X.Z., Nikaido, H., and Poole, K. (2000) Influence of the MexA-MexB-OprM multidrug efflux system on expression of the MexC-MexD-OprJ and MexE-MexF-OprN multidrug efflux systems in *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **46**: 885–891.

Li, X.Z., Zhang, L., and Poole, K. (2002) SmeC, an outer membrane multidrug efflux protein of *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **46**: 333–343.

Li, Y., Mima, T., Komori, Y., Morita, Y., Kuroda, T., Mizushima, T., and Tsuchiya, T. (2003) A new member of the tripartite multidrug efflux pumps, MexVV-WoprM, in *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **52**: 572–575.

Lin, J., Michel, L.O., and Zhang, Q. (2002) CmeABC functions as a multidrug efflux system in *Campylobacter jejuni*. *Antimicrob Agents Chemother* **46**: 2124–2131.

Lin, J., Akiba, M., Sahin, O., and Zhang, Q. (2005) CmeR functions as a transcriptional repressor for the multidrug efflux pump CmeABC in *Campylobacter jejuni*. *Antimicrob Agents Chemother* **49**: 1067–1075.

Liu, L.F., and Wang, J.C. (1978a) DNA–DNA gyrase complex: the wrapping of the DNA duplex outside the enzyme. *Cell* **15**: 979–984.

Liu, L.F., and Wang, J.C. (1978b) *Micrococcus luteus* DNA gyrase: active components and a model for its supercoiling of DNA. *Proc Natl Acad Sci USA* **75**: 2098–2102.

Llanes, C., Hocquet, D., Vogne, C., Benali-Baitich, D., Neuwirth, C., and Pléiat, P. (2004) Clinical strains of *Pseudomonas aeruginosa* overproducing MexAB-OprM and MexXY efflux pumps simultaneously. *Antimicrob Agents Chemother* **48**: 1797–1802.

Low, M.N., and Lamb, H.M. (2000) Gemifloxacin. *Drugs* **59**: 1137–1147.

Luo, N., Sahin, O., Lin, J., Michel, L.O., and Zhang, Q. (2003) In vivo selection of *Campylobacter* isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump. *Antimicrob Agents Chemother* **47**: 390–394.

Madurga, S., Sánchez-Céspedes, J., Belda, I., Vila, J., and Giralt, E. (2008) Binding mechanism of fluoroquinolone to the quinolone resistance-determining region of DNA Gyrase: towards an understanding of the molecular basis of quinolone resistance. *Chem Bio Chem* **9**: 2081–2086.

Magnet, S., Courvalin, P., and Lambert, T. (2001) Resistance-nodulation-cell division-type efflux pump involved in amnoglycoside resistance in *Acinetobacter baumannii* strain BM4454. *Antimicrob Agents Chemother* **45**: 3375–3380.

Mammeri, H., Van De Loo, M., Poirel, L., Martinez-Martinez, L., and Nordmann, P. (2005) Emergence of plasmid-mediated quinolone resistance in *Escherichia coli* in Europe. *Antimicrob Agents Chemother* **49**: 71–76.

Manjunatha, U.H., Dalal, M., Chatterji, M., Radha, D.R., Winsiewaraih, S.S., and Nagaraja, V. (2002) Functional characterization of mycobacterial DNA gyrase: an efficient decatenase. *Nucleic Acids Res* **30**: 2144–2153.

Marchand, I., Damier-Piolle, L., Courvalin, P., and Lambert, T. (2004) Expression of the RND-type efflux pump AdeABC in *Acinetobacter baumanii* is regulated by the AdeRS two-component system. *Antimicrob Agents Chemother* **48**: 3298–3304.

Markham, P.N., and Neyfakh, A.A. (2001) Efflux-mediated drug resistance in Gram-positive bacteria. *Curr Opin Microbiol* **4**: 509–514.

Marrer, E., Schad, K., Satoth, A.T., Page, M.G.P., Johnson, M.M., and Piddock, L.J.V. (2006) Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* **50**: 685–693.

Martin, R.G., and Rosner, J.L. (2002) Genomics of the marA/soxS/rob regulon of *Escherichia coli*: identification of directly activated promoters by application of molecular genetics and informatics to microarray data. *Mol Microbiol* **44**: 1611–1624.

Martin, R.G., Gillette, W.K., Rhee, S., and Rosner, J.L. (1999) Structural requirements for marbox function in transcriptional activation of *mar/sox/rob* regulon promoters in *Escherichia coli*: sequence, orientation and spatial relationship to the core promoter. *Mol Microbiol* **34**: 431–441.

Martínez-Martínez, L.A., Pascual, A., and Jacoby, G.A. (1998) Quinolone resistance from a transferable plasmid. *Lancet* **351**: 797–799.

Martínez-Martínez, L., Pascual, A., Conejo, M.C., García, I., Joyanes, P., Doménéch-Sánchez, A., and Benedit, V.J. (2002) Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of *Klebsiella pneumoniae* and relationship to extended-spectrum β-lactamase production. *Antimicrob Agents Chemother* **46**: 3926–3932.

Maseda, H., Saito, K., Nakajima, A., and Nakae, T. (2000) Variation of the mexT gene, a regulator of the MexEF-OprN efflux pump expression in wild-type strains of *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* **192**: 107–112.

Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., and Nishino, T. (2000) Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **44**: 2242–2246.

Matsu, Y., Eda, S., Gotoh, N., Yoshihara, E., and Nakae, T. (2004) MexZ-mediated regulation of mexXY multidrug efflux pump expression in *Pseudomonas aeruginosa* by binding to the mexZ-mexX intergenic DNA. *FEMS Microbiol Lett* **238**: 23–28.

Maxwell, A. (1993) The interaction between coumarin drugs and DNA gyrase. *Mol Microbiol* **9**: 681–686.

Mima, T., Sekiya, H., Mizushima, T.M., Kuroda, T., and Tsuchiya, T. (2005) Gene cloning and properties of the RND-type multidrug efflux pumps MexPQ-OpmE and MexMN-OprM from *Pseudomonas aeruginosa*. *Microbiol Immunol* **49**: 999–1002.

Mine, T., Morita, Y., Kataoka, A., Mizushima, T., and Tsuchiya, T. (1999) Expression in *Escherichia coli* of a new multidrug
efflux pump, MexXY, from Pseudomonas aeruginosa. *Antimicrob Agents Chemother* **43**: 415–417.

Mizuno, T., Chou, M.Y., and Inouye, M. (1984) A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). *Proc Natl Acad Sci USA* **81**: 1966–1970.

Morita, Y., Cao, L., Gould, V.C., Avison, M.B., and Poole, K. (2006) *nalD* encodes a second repressor of the *mexAB-oprM* multidrug efflux operon of *Pseudomonas aeruginosa*. *J Bacteriol* **188**: 8649–8654.

Nakamura, S., Nakamura, M., Kojima, T., and Yoshida, H. (1989) gyrA and gyrB mutations in quinolone-resistant strains of *Escherichia coli*. *Antimicrob Agents Chemother* **33**: 254–255.

Nazik, A., Poirel, L., and Nordmann, P. (2005) Further identification of plasmid-mediated quinolone resistance determinant in *Enterobacteriaceae* in Turkey. *Antimicrob Agents Chemother* **49**: 2146–2147.

Ng, E.Y.W., Trucksis, M., and Hooper, D.C. (1994) Quinolone resistance mediated by *norA*: physiologic characterization and relationship to *fliQ*, a quinolone resistance locus on the *Staphylococcus aureus* chromosome. *Antimicrob Agents Chemother* **38**: 1345–1355.

Nikaido, H. (1996) Multidrug efflux pumps of Gram-negative bacteria. *J Bacteriol* **178**: 5853–5859.

Nishino, K., and Yamaguchi, A. (2001) Analysis of a complete library of putative drug transporter genes in *Escherichia coli*. *J Bacteriol* **183**: 5803–5812.

Nunoshita, T., and Demple, B. (1994) A cluster of constitutive mutations affecting the C-terminus of the redox-sensitive SoxR transcriptional activator. *Nucleic Acids Res* **22**: 2958–2962.

Oethinger, M., Podglajen, I., Kern, W.V., and Levy, S.B. (1998) Overexpression of the *marA* or *soxS* regulatory gene in clinical topoisomerase mutants of *Escherichia coli*. *Antimicrob Agents Chemother* **42**: 2089–2094.

Oethinger, M., Kern, W.V., Jellen-Ritter, A.S., McMurray, L.M., and Levy, S.B. (2000) Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in *Escherichia coli* in the absence of the AcrAB efflux pump. *Antimicrob Agents Chemother* **44**: 10–13.

Ogawa, W., Koterasawa, M., Kuroda, T., and Tsuchiya, T. (2006) *KmrA* multidrug efflux pump from *Klebsiella pneumoniae*. *Biopharm Bull* **29**: 550–553.

Oh, H., Stenhoff, J., Jalal, S., and Wretlind, B. (2003) Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant *Pseudomonas aeruginosa* strains. *Microb Drug Resist* **9**: 323–328.

Okeba, H., Ma, D., and Nikaido, H. (1996) AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of *Escherichia coli* multiple-antibiotic-resistance (Mar) mutants. *J Bacteriol* **178**: 306–308.

Olliver, A., Vallé, M., Chaslu-Danca, E., and Cloeckaert, A. (2004) Role of an acrR mutation in multidrug resistance of *in vitro*-selected fluoroquinolone-resistant mutants of *Salmonella enterica* serovar Typhimurium. *FEMS Microbiol Lett* **238**: 267–272.

Olliver, A., Vallé, M., Chaslu-Danca, E., and Cloeckaert, A. (2005) Overexpression of the multidrug efflux operon *acrEF* by insertional activation with IS*1* or IS*10* elements in *Salmonella enterica* serovar Typhimurium DT204 *acrB* mutants selected with fluoroquinolones. *Antimicrob Agents Chemother* **49**: 289–301.

Ostrov, D.A., Hernández-Prada, J.A., Corsino, P.E., Finton, K.A., Le, N., and Rowe, T.C. (2007) Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening. *Antimicrob Agents Chemother* **51**: 3688–3698.

Pan, X.S., and Fisher, L.M. (1999) *Streptococcus pneumoniae* DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. *Antimicrob Agents Chemother* **43**: 1129–1136.

Park, C.H., Robicsek, A., Jacoby, G.A., Sahm, D., and Hooper, D.C. (2006) Prevalence in the United States of *aac(6’)-Ib-cr* encoding a ciprofloxacin-modifying enzyme. *Antimicrob Agents Chemother* **50**: 3953–3955.

Paton, J.H., and Reeves, D.S. (1988) Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use. *Drugs* **36**: 193–228.

Perry, C.M., Balfour, J.A.B., and Lamb, H.M. (1999) Gatifloxacin. *Drugs* **58**: 683–696.

Piddock, L.J.V., White, D.G., Gensberg, K., Pumbwe, L., and Griggs, D. (2000) Evidence for an efflux pump mediating multiple antibiotic resistance in *Salmonella enterica* serovar Typhimurium. *Antimicrob Agents Chemother* **44**: 3118–3121.

Piddock, L.J.V., Johnson, M.M., Simjee, S., and Pumbwe, L. (2002) Expression of efflux pump gene *pmrA* in fluoroquinolone-resistant and -susceptible clinical isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* **46**: 808–812.

Ping, Y., Ogawa, W., Kuroda, T., and Tsuchiya, T. (2007) Gene cloning and characterization of KdeA, a multidrug efflux pump from *Klebsiella pneumoniae*. *Biol Pharm Bull* **30**: 1962–1964.

Pitout, J.D.D., Wei, Y., Church, D.L., and Gergson, D.B. (2008) Surveillance for plasmid-mediated quinolone resistance determinants in *Enterobacteriaceae* within the Calgary Health Region, Canada: the emergence of *aac(6’)-Ib-cr*. *J Antimicrob Chemother* **61**: 999–1002.

Poirel, L., Liard, A., Rodriguez-Martinez, J.M., and Nordmann, P. (2005a) *Vibrioaceae* as a possible source of Qnr-like quinolone resistant determinants. *J Antimicrob Chemother* **56**: 1118–1121.

Poirel, L., Rodriguez-Martinez, J.M., Mammari, H., Liard, A., and Nordmann, P. (2005b) Origin of plasmid-mediated quinolone resistance determinant QnrA. *Antimicrob Agents Chemother* **49**: 3523–3525.

Pomposiello, P.J., and Demple, B. (2000) Identification of SoxS-regulated genes in *Salmonella enterica* serovar Typhimurium. *J Bacteriol* **182**: 23–29.

Poole, K. (2000a) Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. *Antimicrob Agents Chemother* **44**: 2233–2241.
Mechanism of action of and resistance to quinolones

Sánchez-Céspedes, J., Blasco, M.D., Martí, S., Alba, V., Alcaide, E., Esteve, C., and Vila, J. (2008) Plasmid-mediated QnrS2 determinant from a clinical Aeromonas veronii isolate. Antimicrob Agents Chemother 52: 2990–2991.

Sekiya, H., Mima, T., Morita, Y., Kuroda, T., Mizushima, T., and Tsuchiya, T. (2003) Functional cloning and characterization of a multidrug efflux pump, MexHI-OpmD, from a Pseudomonas aeruginosa mutant. Antimicrob Agents Chemother 47: 2990–2992.

Schneiders, T., Ames, S.G.B., and Levy, S.B. (2003) Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob Agents Chemother 47: 2831–2837.

Schulz-Gasch, T., and Stahl, M. (2003) Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J Mol Model 9: 47–57.

Shen, L.L., Mitscher, L.A., Sharma, P.N., O’Donnell, T.J., Chu, D.W.T., Cooper, C.S., et al. (1989) Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 28: 3886–3894.

Sierra, J.M., Marco, F., Ruiz, J., Jimenez de Anta, M.T., and Vila, J. (2002) Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus. Clin Microbiol Infect 8: 781–790.

Sierra, J.M., Martínez-Martínez, L., Vázquez, F., Giralt, E., and Vila, J. (2005a) Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum. Antimicrob Agents Chemother 49: 1714–1719.

Sierra, J.M., Cabeza, J.G., Ruiz, M., Montero, T., Hernandez, J., Mensa, J., et al. (2005b) The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin Microbiol Infect 11: 750–758.

Sobel, M.L., Hocquet, D., Cao, L., Plesiat, P., and Poole, K. (2005a) Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemoter 49: 1782–1786.

Sobel, M.L., Neshat, S., and Poole, K. (2005b) Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa. J Bacteriol 187: 1246–1253.

Sorolloz, A., Gutierrez, J., Jimenez, A., de Dios Luna, J., and Martínez, J.L. (2007) Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-β-lactamase-producing Escherichia coli isolates. J Clin Microbiol 45: 2740–2742.

Stanhope, M.J., Walsh, S.L., Becker, J.A., Italia, M.J., Ingham, K.A., Gwynn, M.N., et al. (2005) Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread. Antimicrob Agents Chemother 49: 4315–4326.

van der Straaten, T., Janssen, R., Mevius, D.J., and van Dissel, J.T. (2004) Salmonella gene rma (ramA) and
multiple-drug-resistant *Salmonella enterica* serovar Typhimurium. *Antimicrob Agents Chemother* **48**: 2292–2294.

Su, X.Z., Chen, J., Mizushima, T., Kuroda, T., and Tsuchiya, T. (2005) AbeM, an H+-coupled *Acinetobacter baumannii* multidrug efflux pump belonging to the MATE family of transporters. *Antimicrob Agents Chemother* **49**: 4362–4364.

Suh, B., and Lorber, B. (1995) Quinolones. *Med Clin North Am* **79**: 869–894.

Sulavik, M.C., Dazer, M., and Miller, P.F. (1997) The *Salmonella* Typhimurium mar locus: molecular and genetic analyses and assessment of its role in virulence. *J Bacteriol* **179**: 1857–1866.

Sulavik, M.C., Houseweart, C., Cramer, C., Jiwni, N., Murgolo, N., Greene, J., et al. (2001) Antibiotic susceptibility profiles of *Escherichia coli* strains lacking multidrug efflux pump genes. *Antimicrob Agents Chemother* **45**: 1126–1136.

Tavío, M.M., Vila, J., Ruiz, J., Ruiz, J., Martin-Sánchez, A.M., and Jiménez de Anta, M.T. (1999) Mechanisms involved in the development of resistance to fluoroquinolones in *Escherichia coli*. *J Antimicrob Chemother* **43**: 735–742.

Tran, J.H., and Jacoby, G.A. (2002) Mechanism of plasmid-mediated quinolone resistance. *Proc Natl Acad Sci USA* **99**: 5638–5642.

Tran, J.H., Jacoby, G.A., and Hooper, D.C. (2005a) Interaction of the plasmid-encoded quinolone resistance protein Qnr with *Escherichia coli* DNA gyrase. *Antimicrob Agents Chemother* **49**: 118–125.

Tran, J.H., Jacoby, G.A., and Hooper, D.C. (2005b) Interaction of the plasmid-encoded quinolone resistance protein Qnr with *Escherichia coli* topoisomerase IV. *Antimicrob Agents Chemother* **49**: 3050–3052.

Truong-Bolduc, Q.C., and Hooper, D.C. (2007) The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and β-lactams in *Staphylococcus aureus*. *J Bacteriol* **189**: 2996–3005.

Truong-Bolduc, Q.C., Zhang, X., and Hooper, D.C. (2003) Characterization of NorR protein, a multifunctional regulator of norA expression in *Staphylococcus aureus*. *J Bacteriol* **185**: 3127–3138.

Truong-Bolduc, Q.C., Dunman, P.M., Strahilevitz, J., Projan, S.J., and Hooper, D.C. (2005) MgrA is a multiple regulator of two new efflux pumps in *Staphylococcus aureus*. *J Bacteriol* **187**: 2395–2405.

Truong-Bolduc, Q.C., Strahilevitz, J., and Hooper, D.C. (2006) NorC, a new efflux pump regulated by MgrA of *Staphylococcus aureus*. *Antimicrob Agents Chemother* **50**: 1104–1107.

Valdezate, S., Vindel, A., Echeita, A., Baquero, F., and Cantó, R. (2002) Topoisomerase II and IV quinolone-resistance determining regions in *Stenotrophomonas maltophilia* clinical isolates with different levels of quinolone susceptibility. *Antimicrob Agents Chemother* **46**: 665–671.

Valdezate, S., Vindel, A., Saéz-Nieto, J.A., Baquero, F., and Cantón, R. (2005) Preservation of topoisomerase genetic sequences during *in vivo* and *in vitro* development of high-level resistance to ciprofloxacin in isogenic *Stenotrophomonas maltophilia* strains. *J Antimicrob Chemother* **56**: 220–223.
Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L.M., and Nakamura, S. (1991) Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35: 1647–1650.

Zgurskaya, H.I., and Nikaido, H. (2000) Multidrug resistance mechanisms: drug efflux across two membranes. Mol Microbiol 37: 219–225.

Zhanel, G.G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A.S., Embil, J., et al. (2002) A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs 62: 13–59.

Zhao, Q., Li, X.Z., Srikumar, R., and Poole, K. (1998) Contribution of outer membrane efflux protein OprM to antibiotic resistance in Pseudomonas aeruginosa independent of MexAB. Antimicrob Agents Chemother 42: 1682–1688.